US 8895586

I'll search for patent US 8895586 in USPTO and CAFC databases.

Let me dig into the claims and any 2026 litigation activity.

Let me check for specific 2026 CAFC activity and the exact claim structures.

US Patent 8,895,586 — Analyst Summary

Scope note / method: This is based on publicly indexed sources reachable by search (Google Patents, PubChem patent record, Justia Patents, DrugPatentWatch, PTAB filings, CourtListener/PTAB docket mirrors). I do not have direct credentialed access to USPTO PatentCenter or the CAFC's own docket system, so the litigation/docket portion below reflects what is publicly indexed rather than a definitive docket pull. I found no CAFC 2026 docket, appeal, or Federal Circuit decision involving patent 8,895,586 — see "Docket check" below. I did not auto-correct any identifier; all numbers are reported as found.

1. Bibliographic identification

Inventor locations (per Justia): Fadini and Manini (Giubiasco), Pietra and Giuliano (Como), Lovati (Mendrisio), Cannella and Venturini (Varese), Stella (US).

2. Abstract (verbatim, as published)

"Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor. The compounds have the general formula (I):"

The abstract is generic because the specification is broad (a Markush formula (I) genus of substituted 4‑phenyl‑pyridines), while the granted claims are narrow and compound-specific.

3. Plain-language overview of the independent claims

The patent has four independent claims — 1, 10, 14, and 18 (with dependents 2–9, 11–13, 15–17, 19–21). All four are method-of-treatment claims. In each, the active agent is drawn as a chemical structure reproduced in the claim (the structure is an image in the patent and is not rendered in the text feeds I retrieved — see uncertainty note).

• Claim 1 — A method of treating emesis in a patient in need of it by administering a therapeutically effective amount of the specified compound (or a pharmaceutically acceptable salt of it). No route, dose, or co-therapy is required. This is the broadest claim.

  • Dependent claims: claim 2 covers CINV/RINV/PONV; 3 moderately emetogenic chemotherapy; 4 highly emetogenic chemotherapy; 5 acute and delayed emesis; 6 administration by injection; 7 dosage 10–200 mg; 8 add palonosetron (or salt); 9 add palonosetron plus dexamethasone.

• Claim 10 — Same treatment, but the claim requires administration via injection. Dependents 11–13 add CINV, acute/delayed emesis, and the 10–200 mg dose.

• Claim 14 — Same treatment, but the compound is administered in combination with palonosetron (or a pharmaceutically acceptable salt) and dexamethasone. Dependents 15–17 add CINV, injection, and the 10–200 mg dose.

• Claim 18 — A further method of treating emesis with a specified compound (a third structure drawn in the claim), with dependents 19–21 addressing injection, the 10–200 mg dose, and optional addition of palonosetron.

Practical reading: These are narrow, structure-specific, method-of-use claims tied to the Helsinn NK1-antagonist program. The commercial relevance is the IV AKYNZEO product: the specification identifies the claimed compound class around the phosphorylation "pro-drug"/piperazinium chemistry, and the compound named in the specification as GA1 — 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium — corresponds to fosnetupitant, the active ingredient in the IV product. The claims also recite combination embodiments with palonosetron and dexamethasone, matching the Orange Book U‑2301 "use in combination with dexamethasone… highly emetogenic chemotherapy" listing.

4. Specification context worth flagging

• The patent is expressly a modified 4‑phenyl‑pyridine case: the background criticizes prior N‑oxide derivatives (U.S. 6,747,026) for lacking physicochemical/biological data, and criticizes U.S. 5,985,856 (Kansas) on N‑phosphoryloxymethyl amines for not showing effects on stability, tolerability, bioavailability, metabolism, or toxicity. The stated object is a new class of NK1 antagonists with enhanced physicochemical and/or biological properties.
• Independent claims recite a single compound, not the formula (I) genus. The genus is claimed only in the specification; note the express disclaimer in the description: "In another embodiment, the invention excludes all N-oxide forms," with a proviso about non-pyridine N‑oxides.
• The specification lists compounds GA1–GA8, spanning phosphonooxymethyl piperazinium salts (GA1), acyloxymethyl quaternary salts (GA2, GA3), and various mono/di-N-oxide forms (GA4–GA8).

5. Docket check — what exists and what does not

District court / ANDA litigation (confirmed): Google Patents flags a U.S. case in the District of New Jersey (3:22‑cv‑04635 and 2:22‑cv‑04635) as family litigation. CourtListener documents in D. N.J. confirm a Helsinn action against Gland Pharma on ANDA No. 217374 (fosnetupitant chloride hydrochloride / palonosetron hydrochloride, 235 mg/0.25 mg per 20 mL IV vials). The '586 patent is one of the asserted patents (Count II of the complaint), alongside U.S. 8,426,450; 9,186,357; 9,403,772; 9,908,907; 10,208,073; 10,624,911; 10,717,721; 10,828,297; 11,312,698; 11,529,362.

PTAB (confirmed, but not on this patent): Azurity Pharmaceuticals filed IPRs against related Helsinn patents — IPR2025‑00945 (8,623,826), ‑00946/‑00947 (9,186,357), ‑00948 (9,943,515, instituted), ‑00949 (10,828,297). None of these challenges is against 8,895,586. I found no IPR directed at the '586 patent.

CAFC 2026 docket (not found): I searched for a 2026 Federal Circuit appeal or decision naming 8,895,586 and found none. Searches returned unrelated 2026 CAFC/Federal Circuit material (e.g., Netlist v. Micron, Biofer v. Vifor, Moskowitz Family v. Globus Medical, and the Supreme Court's Hikma v. Amarin No. 24‑889 merits ruling of June 4, 2026). The coincidental "889" in the Supreme Court docket number 24‑889 is not patent 8,895,586 and should not be conflated with it. If a 2026 CAFC appeal involving the '586 patent exists, it is not reflected in the indexed sources I can reach, and I cannot confirm it.

6. Explicit uncertainties

1. Claim drawing content: The chemical structures in independent claims 1, 10, 14, and 18 are rendered as images. Text extractions (DrugPatentWatch, Justia) preserve the claim language but omit the structure. I infer from the NDA/product and specification that the claimed compound is the GA1/fosnetupitant structure, but I have not visually verified which of the GA1–GA8 structures appears in each of the four independent claims. Verify against the granted patent drawing sheets before relying on this.
2. Assignee history: The face and Google Patents show an "Individual" original assignee with a 2018 assignment to Helsinn Healthcare SA; PubChem lists the inventors as assignees. The current owner of record is Helsinn Healthcare SA.
3. Expiration: The 2032‑05‑23 date appears in both Google Patents and the Orange Book listing; whether it depends on PTA/terminal disclaimer interactions with the parent family (e.g., the EP 2785706 family) should be confirmed against the patent's term-adjustment data.
4. Docket coverage: Absence of a CAFC 2026 docket in my results is not proof that none exists — it means it was not surfaced by the sources I could search.

I'll research litigation involving US patent 8,895,586 specifically, checking litigation databases and court records.

I have the core case. Let me check for any additional defendants or later cases involving this patent.

Let me check whether any additional Akynzeo IV defendants or later cases also asserted this patent.

Litigation Involving U.S. Patent No. 8,895,586

Bottom line: Exactly one court case is publicly indexed as asserting U.S. 8,895,586 ("the '586 patent"). It is a Hatch-Waxman (ANDA) infringement action brought by the patent owner, Helsinn Healthcare S.A., against Gland Pharma Limited in the District of New Jersey. It was resolved by a consent judgment and dismissal in January 2023. No Federal Circuit appeal, no PTAB trial, and no other district-court case naming the '586 patent was found.

The one known case

The '586-specific allegations and counterclaims

• Gland's June 2, 2022 Paragraph IV Notice Letter certified that the '586 patent (together with the '450, '357, '772, '907, '073, '911, '721 and '297 patents) was invalid, unenforceable, and/or not infringed; a second letter of July 11, 2022 covered the '698 patent.
• Gland's Third Counterclaim sought a declaratory judgment of non‑infringement of any valid claim of the '586 patent; its Fourth Counterclaim sought a declaratory judgment of invalidity of the '586 patent (raised under 35 U.S.C. §§ 101, 102, 103, 112, 116, § 282(b), and double patenting).
• Per the consent judgment: no court decision issued on infringement or validity — "No decision has been obtained by the parties from this Court regarding these charges of infringement or these defenses and counterclaims." Gland did not rebut the statutory presumption of validity (expressly without prejudice to its invalidity defenses), and admitted only the technical § 271(e)(2)(A) act of infringement based on its ANDA submission. Injunction/entry-date terms restricted Gland's generic product launch until a date left blank in the public redacted version.
• No merits ruling on the '586 exists. The case ended in settlement/consent, so the patent's validity was never adjudicated.

Sources: D.N.J. docket via CourtListener (docket 63601016, docs #25, #31, #48, #50) — https://www.courtlistener.com/docket/63601016/helsinn-healthcare-sa-v-gland-pharma-limited/ ; Consent Judgment PDF — https://paragraphfour.com/wp-content/uploads/2022/07/njdc22cv4635CJ.pdf ; Gland counterclaims PDF — https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf ; DrugPatentWatch patent-litigation page for 8,895,586 — https://www.drugpatentwatch.com/p/litigation/patent/index.php?query=8895586 ; IPWatchdog filings roundup (July 29, 2022) — https://ipwatchdog.com/2022/07/29/patent-filings-roundup-future-waco-patent-cases-headed-wheel-ax-wireless-launches-wifi-6-campaign-helsinn-paragraph-iv-litigation/

Related proceedings that do NOT involve the '586 patent (flagged to prevent misattribution)

So the record is not confused with family siblings:

• Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A. — IPR2025‑00945/‑00946/‑00947/‑00948/‑00949 (filed 2025‑05‑01). These target U.S. 8,623,826; 9,186,357 (two petitions); 9,943,515; and 10,828,297 — not the '586. (Per the DrugPatentWatch PTAB listing for "AKYNZEO"/"NETUPITANT; PALONOSETRON HYDROCHLORIDE.")
• Helsinn's ALOXI® palonosetron litigations (e.g., Helsinn v. Teva, Helsinn v. Sagent, D.N.J. 2:16‑cv‑00173, and the associated Helsinn Healthcare v. Teva Supreme Court case, 586 U.S. ___ (2019)) involve the palonosetron patents (e.g., '724, '725, '424, '219, '094) — not the '586.

Explicit uncertainties

1. Case-number prefix conflict (2 vs. 3). The complaint/counterclaim caption and the IPWatchdog table use 2:22‑cv‑04635; Google Patents and Unified Patents links use 3:22‑cv‑04635. I could not resolve which is the official docket prefix and report both as found, per the rule against auto-correcting identifiers.
2. Termination-date discrepancy. DrugPatentWatch records the docket as terminated 2022‑12‑23, but the Consent Judgment/Dismissal Order on CourtListener is dated January 18, 2023 (entered January 19, 2023). Treat the January 2023 consent judgment as the operative disposition.
3. Completeness. My search was limited to publicly indexed litigation aggregators (DrugPatentWatch, CourtListener, Unified Patents/Google Patents litigation panels, IPWatchdog). I found no other U.S. district-court case, ITC action, or Federal Circuit appeal asserting the '586 patent, and no PTAB trial naming it. Absence in these sources is not proof of nonexistence — a party-name and patent-number query at PACER and at the PTAB E2E portal should be run before relying on this as definitive. Additionally, my final verification search returned a tool-limit message, so the last planned cross-check did not complete.

Summary: The only known litigation involving U.S. 8,895,586 is Helsinn Healthcare S.A. v. Gland Pharma Limited, D.N.J. (No. 22‑4635 / 2:22‑cv‑04635 / 3:22‑cv‑04635), filed July 18, 2022, resolved by consent judgment and dismissal on January 18–19, 2023, with no merits ruling on the patent.

I'll start by verifying the structured data and then searching for any PTAB activity, litigation, and appeals related to this patent.

Let me drill into specific petitions and confirm whether any target the '586 patent.

No AIA trial against the '586 yet. Let me verify with targeted searches on possible petitioners and on the '586's own PTAB record.

PTAB Proceedings on US 8,895,586

Bottom line up front: there are zero AIA trial proceedings on this patent. The structured "PTAB proceedings on file" block is the canonical list from the USPTO Open Data Portal and it is empty. My independent web checks (PTAB dockets, Docket Alarm PTAB search, IPWatchdog litigation roundups, CourtListener filings) surface no IPR, PGR, or CBM naming US 8,895,586. The only PTAB activity in the Helsinn/Akynzeo patent family in 2025 targets sibling patents, not the '586 — those are covered below as context, explicitly flagged as not proceedings on this patent.

Proceedings overview

Total AIA trial proceedings on US 8,895,586: 0 — breakdown: active 0 / claims invalidated 0 / claims sustained 0 / settled 0 / institution denied 0.

The defensive posture this gives a defendant is not "the patent has survived IPRs and is hardened," and it is not "the claims are dead." It is the third, less comfortable posture: the '586 is an untested, fully-intact patent. Its claims have never been construed or invalidated by the Board, but they also carry no PTAB validity finding and no § 315(e)(2) estoppel shield. Nothing in the record stops a first-ever IPR petition against it — except the statute-of-limitations problem facing anyone already served (see below).

(Source: structured ODP block in this prompt; corroborated at https://patents.google.com/patent/US8895586/en, whose "Family has litigation" panel lists only the New Jersey district court case and no PTAB link.)

No proceedings on file

There is no IPR, PGR, or CBM docket to report for US 8,895,586. Consequently I cannot report a judge panel, petition grounds, institution decision, Final Written Decision, settlement, or Federal Circuit appeal — none exist, and I will not manufacture them. Please treat any downstream "claim 1 was canceled in IPR20XX-XXXXX" statement about the '586 as false until a real docket is produced.

Two caveats on that finding, stated honestly:

• The ODP block is authoritative but ingest-lagged. New petitions filed in the last few weeks could exist without appearing in it.
• My verification is web-derived, not a live PTAB E2E query. The authoritative check is a party-name and patent-number search at USPTO PTAB E2E / PTAB Decisions (https://ptacts.uspto.gov/ptacts/) and the PTAB public search portal (https://developer.uspto.gov/ptab-api/). I recommend running both before relying on the zero count in a filing.

Context only — sibling Helsinn IPRs (do NOT confuse with the '586)

These are real, verified 2025 proceedings, and they are the reason a sloppy search will make you think the '586 has been challenged. None of them names US 8,895,586.

IPR2025-00945 / -00946 / -00947 / -00948 / -00949 — Azurity Pharmaceuticals, Inc. v. Helsinn Healthcare S.A.

• Type: Inter Partes Review (five petitions)
• Filed: 2025-05-01 (filing date accorded 2025-06-04); all filed the same day
• Patents challenged (verbatim from the Acting Director's referral decision): IPR2025-00945 — Patent 8,623,826 B2; IPR2025-00946 — Patent 9,186,357 B2; IPR2025-00947 — Patent 9,186,357 B2; IPR2025-00948 — Patent 9,943,515 B2; IPR2025-00949 — Patent 10,828,297 B2. Per the Acting Director's decision, the decision states: "IPR2025-00945 (Patent 8,623,826 B2) IPR2025-00946 (Patent 9,186,357 B2) IPR2025-00947 (Patent 9,186,357 B2) IPR2025-00948 (Patent 9,943,515 B2) IPR2025-00949 (Patent 10,828,297 B2)". No US 8,895,586.
• Status: Trial instituted in all five. Board Institution Decision: Grant on 2025-11-19, with scheduling orders the same day.
• Judge panel: For IPR2025-00947 only, Docket Alarm lists Judges Michael J. Fitzpatrick, Sheridan K. Snedden, and Christopher G. Paulraj. I have not verified panels for the other four dockets.
• Petition grounds: § 103 obviousness, pre-AIA versions, with grounds allocated across parallel petitions (e.g., in IPR2025-00947 against the '357: Ground 1 — claims 1, 5-10, 17 over Herrstedt + Bös; Ground 2 — claims 18-19, 25-27, 30-32 over Herrstedt + Bös + Herrington; Ground 3 — claim 20 over Herrstedt + Bös + Herrington + ALOXI; Grounds 5-8 — further dependent claims over combinations adding Hargreaves and Bonadeo). The '357 petition states it "covers 49 of 133 closely related claims spread over four patents." Separately, § 112 arguments were raised in the § 325(d)/discretionary-denial briefing.
• Discretionary denial / Director referral: Helsinn filed a request for discretionary denial under Fintiv / § 325(d); Azurity opposed. Acting Director Coke Morgan Stewart denied discretionary denial and referred the petitions to the Board, holding that "discretionary denial of institution is not appropriate in these proceedings" and that "it is an appropriate use of Office resources to review the Petitions to determine whether or not the Office made a material error." Docket entries place the Director referral at 2025-09-19.
• Post-institution: Patent Owner's Response filed 2026-02-25 (IPR2025-00947); Petitioner objections 2026-03-04. No Final Written Decision had issued as of the latest docket entries I could retrieve (early March 2026). With institution on 2025-11-19, the statutory FWD deadline is approximately 2026-11-19.
• Key sources: https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557835](/patent/1557835)/download-documents?artifactId=y6IrpDZshKUiiFxv9niHSqbJgCBiIoOXIntwhciUvoy8nIRpQCyXDI (Acting Director referral decision); https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf (IPR2025-00947 petition); Docket Alarm dockets for IPR2025-00945 through -00948.
• Defensive value for the '586: none, directly. These proceedings cannot cancel, narrow, or estop anything about the '586. Their indirect value is evidentiary and tactical — the same prior-art family (Herrstedt, Bös, ALOXI Label, Herrington, Hargreaves, Bonadeo) is being litigated against the closely related netupitant/palonosetron patents, and the Board's claim constructions and validity reasoning there will be persuasive (not binding) authority for a future '586 challenge. Also note the estoppel asymmetry: Azurity will be estopped under § 315(e)(2) as to the patents it actually challenged — the '586 is not among them.

District court track record for the '586 (relevant because there is no PTAB record)

Helsinn Healthcare S.A. v. Gland Pharma Limited, D.N.J. No. 3:22-cv-04635-ZNO-LHG (a/k/a 2:22-cv-04635)

• Filed: 2022-07-18 (Helsinn filed within 45 days of receiving Gland's 2022-06-02 Paragraph IV notice).
• Patents asserted: '450, '586, '357, '772, '907, '073, '911, '721, '297 and '698 — ten patents on Akynzeo IV.
• Gland's '586 counterclaims (Third and Fourth Counterclaims, D.J. Act): declaration of non-infringement and declaration of invalidity of all claims of the '586 under 35 U.S.C. §§ 101, 102, 103, 112, 116, § 282(b), and double patenting.
• Gland's pleaded '586 art: "As a sufficient example, as described in the First Notice Letter, all claims of the '586 patent are at least invalid as obvious under § 103 in light of at least the following prior art: Bös; WO '846; DeGoey; Funk; Krise I; Oslob; ALOXI (palonosetron HCl) Injection for Intravenous Use Label ('ALOXI Label'); and EMEND (fosaprepitant dimeglumine) for injection Label ('EMEND Label'). Additionally, the claims are invalid as indefinite and not enabled with respect to the pharmaceutically acceptable salt limitations."
• Disposition: I could not confirm a final judgment or settlement from the sources retrieved. Azurity's 2025 briefing asserts, without support, that "Helsinn paid Gland to go away rather than face a defense" — that is an advocacy characterization in a PTAB opposition brief, not evidence of a settlement, and I flag it as unverified.
• Source: https://storage.courtlistener.com/recap/gov.uscourts.njd.[499051](/patent/499051)/gov.uscourts.njd.499051.25.0.pdf (Gland's Answer and Counterclaims). Docket: https://www.courtlistener.com/docket/64851089/helsinn-healthcare-sa-v-gland-pharma-limited/

Orange Book posture (verified): the '586 is listed for Akynzeo (NDA 210493, both the powder and solution presentations) under use code U-2301 only — a method-of-use listing — with a listed expiration of 2032-05-23, submitted 2018-05-17 (product 001) and 2020-06-24 (product 002). Consistent with the patent's title, Methods of treating emesis, this indicates the asserted claims are treatment-method claims. I have not independently reviewed the claim text, so do not assume claim language, claim count, or claim numbering without pulling the patent.

Strategic summary

Claim status on the '586: all claims are UNTESTED. None are canceled, none have been confirmed by the Board. There is no FWD to cite, no Certificate of Correction, and no estoppel order. If you are working from a template that asks "which claims survived the IPR," the correct answer for this patent is "not applicable — there has been no IPR." Anyone asserting the '586 today asserts an unstained patent; anyone defending against it has no administrative record to lean on and no admission by the patent owner.

Estoppel landscape: clean slate against the '586. Because no IPR or PGR has been instituted on this patent, § 315(e)(2) estoppel does not attach to it from any petitioner. The practical gates are elsewhere: (i) § 315(b) — a petition is time-barred if the petitioner (real party in interest or privy) was served with a complaint alleging infringement of the patent more than one year earlier; Gland was on notice in mid-2022, so Gland is long since time-barred on the '586; (ii) § 315(a)(3) confirms that a counterclaim challenging validity is not a "civil action" for § 315(a)(1) purposes, so the counterclaim route alone would not have barred Gland but for § 315(b); and (iii) any new defendant with a fresh complaint served within the last year has a live IPR window and no estoppel to overcome. All of Gland's pleaded prior-art combinations — Bös, WO '846, DeGoey, Funk, Krise I, Oslob, ALOXI Label, EMEND Label, plus the § 112 salt-limitation theories — remain fully available grounds for a first petitioner, unconstrained by any prior Board treatment.

Pattern signals. Helsinn is a repeat PTAB litigant but always on the palonosetron side of its portfolio, never (so far) on the '586: PGR2014-00010 (US 8,598,219, petitioner Accord Healthcare, filed 2014-09-02); IPRs on US 8,729,094 (petitioner Dr. Reddy's Laboratories, filed 2015-07-03); and PGR2016-00008 (US 9,173,942, Dr. Reddy's, filed 2016-02-05). In 2025, Azurity Pharmaceuticals filed five IPRs in a single day against five Helsinn patents — a coordinated, resource-intensive campaign — and notably did not include the '586, even though the '586 is listed on the same Akynzeo IV NDA and is asserted in the Gland case. There is no defensive aggregator (Unified Patents, RPX, etc.) in the chain for this patent. Helsinn does fight discretionary denial aggressively (it filed Fintiv/§ 325(d) briefing in all five Azurity cases), so a future petitioner should expect a contested institution phase. The correlation worth noting: patents asserted in Hatch-Waxman litigation eventually attract IPRs; the '586's absence from the 2025 Azurity wave most plausibly reflects § 315(b) timing (Gland-era service) rather than any assumption that the claims are invulnerable.

Recommended next steps

1. If you are a defendant already served more than one year ago: your IPR window on the '586 is closed by § 315(b). Your invalidity case lives in the district court under §§ 102/103/112, and the Gland counterclaims give you a ready-made art map (Bös; WO '846; DeGoey; Funk; Krise I; Oslob; ALOXI Label; EMEND Label) to build on. Consider ex parte reexamination, which carries no § 315(b) bar and no estoppel, as an administrative fallback — though it lacks the Board's discovery and expert-cross-examination tools that the Acting Director expressly favored in the Azurity referral decision.

2. If you were served within the last 12 months (or face only a demand letter): an IPR on the '586 is procedurally available and, per the ODP block, would be the first-ever AIA challenge to it. Ground the petition on the Gland art set and add the § 112 indefiniteness/enablement attack on the "pharmaceutically acceptable salt" limitations. Build the petition to survive Fintiv and § 325(d): the Director's 2025-09-19 referral decision in the Azurity cases shows this administration weighing material examiner error heavily against settled-expectation arguments, so frame the theory as examiner error (the allowability of the '586 family rested on asserted unexpected synergy from the netupitant/palonosetron combination) rather than as a routine obviousness re-run.

3. Do not cite nonexistent proceedings. If a demand letter or an expert report cites an IPR number against the '586, demand the docket. The correct citation set for this patent is the district court case, not the Board.

4. Verify before filing. Because my zero-count rests on the ODP block plus web corroboration rather than a live PTAB E2E query, run a final patent-number and assignee search at https://ptacts.uspto.gov/ptacts/ immediately before you rely on "no PTAB activity." If a first petition has been filed recently, that materially changes both the estoppel analysis under § 315(e)(2) and the strategic value of joining versus filing separately.

Sources cited: https://patents.google.com/patent/US8895586/en · https://ptacts.uspto.gov/ptacts/public-informations/petitions/1557835/download-documents?artifactId=y6IrpDZshKUiiFxv9niHSqbJgCBiIoOXIntwhciUvoy8nIRpQCyXDI · https://paragraphfour.com/wp-content/uploads/2025/05/ipr25-0947P.pdf · https://storage.courtlistener.com/recap/gov.uscourts.njd.499051/gov.uscourts.njd.499051.25.0.pdf · https://fda.report/applications/210493

I'll research the assignment record for US 8,895,586. Let me start with the USPTO Assignment Center records and Google Patents legal events.

Let me try to access the assignment records directly and check Google Patents assignment details.

I've gathered what's retrievable. Note up front: I was unable to retrieve the reel/frame numbers or the recorded correspondent for this patent's assignments — those live behind the USPTO Assignment Center's record-detail pages, which did not render to my search tools (the searches returned unrelated documents and noise). I will not fabricate reel/frame numbers or correspondent names. What follows is built on the authoritative Google Patents legal-events record (contained in the patent text supplied for this analysis), which gives conveyance type, assignor, assignee, and date but omits reel/frame and correspondent. I flag each gap explicitly.

Inventors

Eight named inventors (per the granted patent). Locations from the Justia record cited in the earlier summary; employer affiliation is inferred from the location/role pattern and flagged where not certain.

Unusual patterns to note (evidence-based, not inferred):

1. A non-inventor appears as an assignor in the 2018 record. The 2018-01-02 Helsinn assignment lists nine assignors — the eight inventors plus "BRAGLIA, RICCARDO." Riccardo Braglia is not a named inventor of the '586. The Braglia family founded Helsinn (Gabriele Braglia, 1976, per Marketscreener), so this strongly suggests a principal/founder-employee interest was swept into the corporate assignment. This is the single most notable departure from a clean inventor→company chain and is worth a targeted Assignment Center pull.
2. Stella is a university inventor assigning to a commercial company. His Kansas-origin inventorship on a Helsinn-owned patent implies an academic–industry collaboration; if any Kansas rights were retained, that would be a standing/ownership issue. The 2018 assignment (listing Stella as assignor to Helsinn) indicates it was cleaned up.
3. No evidence of inventor departure within 12 months of filing. I found nothing supporting the "all inventors leave / fire-sale" pattern; the inventors appear to have stayed with Helsinn's R&D (Fadini, Manini, Pietra, Giuliano, Lovati, Cannella, Venturini are Helsinn personnel). The 2018 assignment was a corporate clean-up, not a departure event.

Original assignee

Entity named on the issued patent (face): "Individual." Google Patents shows the original assignee as "Individual" and the 2013 application was filed with the inventors as applicants — i.e., no corporate assignment was of record at grant (2014-11-25). The patent was not re-assigned to Helsinn Healthcare SA until 2018-01-02 (see below). This is a real, verifiable feature of the record and explains the "Individual" flag.

• Actual operating owner (post-2018): Helsinn Healthcare SA (Swiss pharma; Via Pian Scairolo 9, CH-6912 Lugano-Pazzallo; founded 1976). Primary line of business: oncology supportive care — antiemetics (Aloxi/palonosetron; Akynzeo/netupitant; Akynzeo IV/fosnetupitant). Status: operating. It is an active licensor AND a repeat patent plaintiff (see the earlier Litigation section: Helsinn v. Gland Pharma, D.N.J. 3:22-cv-04635; earlier Helsinn v. Teva reaching the Supreme Court (No. 17-1229, decided Jan. 22, 2019)).
• Did it ship a product embodying the claims? Yes. The '586 (claims drawn to a 4‑phenyl‑pyridine NK1‑antagonist — the specification's GA1 = fosnetupitant) is Orange Book–listed for AKYNZEO IV (fosnetupitant chloride HCl / palonosetron HCl), NDA 210493, use code U‑2301, first approved April 19, 2018. Since only Helsinn and Gland are in the record as to this NDA, this is an operating-company product, not a licensing shell.
• Current status of the entity: Operating, privately held (Helsinn family-controlled; Braglia principals). The 2022 security interest (below) indicates secured corporate financing, not distress.

Assignment timeline

The USPTO Assignment Center record-detail pages (reel/frame + correspondent) were not retrievable through my tools. The events below come from the Google Patents legal-events record (which mirrors the Assignment Center but suppresses reel/frame and correspondent). No reel/frame numbers or correspondent names can be stated without fabrication, so those fields are marked "not retrieved." I have not invented them.

2018-01-02 (recorded; execution date not shown in the source) — Reel/frame not retrieved

• Conveyance: Assignment ("ASSIGNMENT OF ASSIGNORS INTEREST — SEE DOCUMENT FOR DETAILS")
• Assignor: FADINI, LUCA; MANINI, PETER; BRAGLIA, RICCARDO; CANNELLA, ROBERTA; GIULIANO, CLAUDIO; LOVATI, EMANUELA; PIETRA, CLAUDIO; VENTURINI, ALESSIO; STELLA, VALENTINO J (nine assignors)
• Assignee: HELSINN HEALTHCARE SA
• Correspondent: not retrieved
• Context: ownership clean-up / original-entitlement assignment — the application had been filed naming the "Individual" inventors, and the rights were formally conveyed to the operating company. Timing (recorded Jan. 2018) precedes the AKYNZEO IV approval (Apr. 19, 2018) and Orange Book listing submission (May 17, 2018), consistent with cleaning title ahead of the NDA-era patent listing. Not a fire-sale.

2022-12-30 (recorded; execution date not shown) — Reel/frame not retrieved

• Conveyance: Security Interest ("SECURITY INTEREST — SEE DOCUMENT FOR DETAILS")
• Assignor: HELSINN BIREX PHARMACEUTICALS LIMITED; HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.
• Assignee: HAMILTON SA LLC (as collateral/secured party)
• Correspondent: not retrieved
• Context: securitization / corporate financing — a negative-pledge collateral grant over the Helsinn patent estate (three Helsinn entities as grantors to a single collateral agent), a standard secured-lending arrangement. Not a transfer of beneficial ownership and not a shell-entity transfer.

2023-09-20 (recorded; execution date not shown) — Reel/frame not retrieved

• Conveyance: Release By Secured Party ("RELEASE BY SECURED PARTY — SEE DOCUMENT FOR DETAILS")
• Assignor: HAMILTON SA LLC
• Assignee: HELSINN HEALTHCARE SA; HELSINN BIREX PHARMACEUTICALS LIMITED; HELSINN THERAPEUTICS (U.S.), INC.
• Correspondent: not retrieved
• Context: release of the 2022 security interest — the collateral encumbrance was discharged; ownership remained with Helsinn throughout. This closes the financing loop and leaves Helsinn Healthcare SA as the (unencumbered) owner.

Net effect of the recorded chain: inventors (+ one non-inventor principal) → Helsinn Healthcare SA (2018, assignment) → encumbered by Hamilton SA LLC (2022, security interest) → released back to Helsinn (2023). No transfer to any licensing entity or known asserter at any point.

Timeline diagram

timeline
    title Ownership of US 8895586
    2011 : Priority provisional filed
    2013 : Application filed
         : Pre-grant publication
    2014 : Patent granted
    2018 : Inventors assign to Helsinn Healthcare
    2022 : Security interest to Hamilton SA LLC
         : Helsinn sues Gland Pharma in D NJ
    2023 : Security interest released to Helsinn

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The only assignment is inventors → Helsinn Healthcare SA, an operating pharmaceutical company that markets AKYNZEO (the embodying product) and has no "IP/Holdings/Licensing/Ventures" suffix on any recorded assignee. No single-purpose LLC ever takes title.

2. Known asserter in the chain — not present. Neither assignee (Helsinn Healthcare SA; Hamilton SA LLC) matches any public NPE list (Acacia, Marathon, IV, IPNav, Wi‑LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Erich Spangenberg entities, etc.). Helsinn is the plaintiff here, suing competitors — the opposite of the NPE posture. Hamilton SA LLC is a collateral/secured party in a financing, not an asserter; its only role is a security interest (2022-12-30) that it released (2023-09-20).

3. Repeat correspondent across the chain — unclear / cannot assess. This signal turns entirely on the recorded correspondent, which I could not retrieve for any of the three events. Because only three recordings exist across 11 years, and two of them are a financing-and-release pair (Hamilton), the recurrence test is unlikely to produce a pattern — but I cannot make the call without the correspondent fields. Recommend pulling the correspondent for all three reel/frame entries at the Assignment Center before scoring this signal.

4. Cascading transfers — not present. Three events over ~11 years, no chained LLCs, no shared-anonymous-address behavior, no sub-24-month sequence of title transfers.

5. Pre-litigation transfer — not present. The first (and only) infringement suit naming the '586, Helsinn v. Gland Pharma, D.N.J. 3:22-cv-04635, was filed 2022-07-18. The only 2022 event in the assignment record — the Hamilton security interest — was recorded 2022-12-30, five months after the suit and is a financing lien, not a transfer to an asserter. There is no title transfer within six months before suit; the plaintiff (Helsinn) already owned the patent from 2018.

6. Bankruptcy fire-sale — not present. No Chapter 7/11 proceedings involving Helsinn or any assignee appear in the record. The 2022 security interest and 2023 release are ordinary secured financing, the inverse of a distressed sale.

7. Privateering — not present. Helsinn did not transfer the '586 to an NPE to assert on its behalf; Helsinn asserted the patent itself against Gland Pharma. No SEC filing, EFF, or Patent Progress coverage indicates a privateering arrangement.

8. Defensive aggregator (anti-NPE) — not present. The chain terminates at Helsinn Healthcare SA (an operating, asserting company), not at RPX, AST, LOT, Unified, or OIN. The patent is not neutralized.

Verdict

Operating-company assertion.

The recorded chain is a clean inventors-to-operating-company assignment (2018-01-02, inventors + non-inventor Braglia → Helsinn Healthcare SA), followed only by a secured-financing lien to Hamilton SA LLC (2022-12-30) and its release back to Helsinn (2023-09-20) — no licensing entity, no known asserter, no shell-entity transfer at any link. Helsinn ships the embodying product (AKYNZEO IV, NDA 210493, Orange Book use code U‑2301) and sued an actual generic competitor (Gland Pharma, D.N.J. 3:22-cv-04635) on this patent, which is the classic operating-company-assertion posture. The two assignment-record anomalies worth a follow-up pull are (i) the non-inventor Riccardo Braglia appearing as a 2018 assignor, and (ii) the reel/frame and correspondent fields, which I could not retrieve and did not fabricate.

Verification link (Assignment Center, search by patent number 8895586): https://assignmentcenter.uspto.gov/ (legacy mirror: https://assignment.uspto.gov/patent/index.html)

Caveats: (1) Reel/frame numbers and correspondents of record are not reported because I could not retrieve them — do not treat their absence here as "no correspondent." (2) I relied on the Google Patents legal-events record (supplied patent text) for conveyance type, assignor, assignee, and date; execution dates shown as recorded dates may differ from actual execution dates. (3) Riccardo Braglia's inclusion as assignor is a factual observation from the record; the reason (founder/principal interest) is my inference and should be confirmed against the assignment instrument itself.

I'll research the prior art cited on the face of US 8,895,586 and in its prosecution, focusing strictly on this patent number.

Let me verify the disclosure content of the key cited references and check the prosecution history for the '586 patent specifically.

Let me verify the remaining cited references and check the prosecution history for any additional applied art.

Prior Art Analysis — U.S. Patent No. 8,895,586 B2

Subject patent: U.S. 8,895,586 B2, "Methods of treating emesis" (App. 13/864,381; filed Apr. 17, 2013; granted Nov. 25, 2014; priority U.S. Prov. 61/564,537, Nov. 29, 2011; Applicant/assignee Helsinn Healthcare SA). Divisional of App. 13/478,361 (now U.S. 8,426,450 B1).

Identifying the correct patent: All results below are keyed to 8,895,586 and its App. No. 13/864,381. Results for other numbers (e.g., 8,426,450; 9,908,907; 10,717,721; the other Helsinn filings) were discarded except where they are family members relevant to anticipation/obviousness, and are labeled as such.

Method note: The prior-art citations on the face of the '586 were cross-verified against four independent mirrors (Google Patents, Justia, FreePatentsOnline, PubChem patent record). There is a discrepancy in the count of cited U.S. patents: Google Patents renders only six ("Citations" table), while Justia/FreePatentsOnline and PubChem each render nine (nine U.S. patents + two NPL). The authoritative face-of-patent set is the nine — Google's table truncates. The three present in Justia/FPO/PubChem but missing from Google's table are U.S. 6,479,483; 6,747,026; and 6,806,370. I did not auto-correct any number; all are reported as found.

I could not retrieve the PTO-892 / Notice of References Cited from the file wrapper of App. 13/864,381 directly; the face-of-patent listing is therefore treated as the complete record of cited art.

1. Complete cited-reference set (face of the '586)

1a. U.S. patent documents (nine)

1b. Non-patent literature (two)

Inconsistency to flag (do not auto-correct): The body of the '586 specification cites the Kramer reference as "Science 281 (5383), 1640–1645, 1988," whereas the face-of-patent "Other References" list and the actual journal record give 1998. The "1988" in the specification body is a typographical error in the source document; the reference is the 1998 Science paper. I report both as found.

2. Reference-by-reference analysis and § 102 assessment

Preliminary point on the claims. Claims 1–21 are all method-of-treatment claims, and each independent claim (1, 10, 14, 18) recites a specific drawn chemical structure as the administered agent (optionally as a pharmaceutically acceptable salt), with dependents adding indication (CINV/RINV/PONV, moderately/highly emetogenic chemotherapy, acute+delayed), route (injection), dose (10–200 mg), and co-therapy (palonosetron ± dexamethasone). For a single reference to anticipate under § 102, it must disclose every element of the claim, arranged as claimed — including the specific administered compound used in the claimed method. None of the nine cited U.S. patents or two NPL items discloses the specific compounds drawn in the '586 claims. The analysis below therefore identifies each reference's relevance and its § 103 (obviousness) role, and states explicitly where § 102 anticipation does not lie.

(Uncertainty carried forward from the earlier sections: the structures in the claim images could not be visually verified through the text feeds. Based on the specification's GA-series and the Orange Book U-2301 listing for fosnetupitant, the claims most plausibly recite the GA1 structure — 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) — and/or its salts. One exception to the § 102 "no anticipation" conclusion is flagged under US 6,297,375 below.)

1. US 5,985,856 — Stella et al. (University of Kansas), granted Nov 16, 1999

• Full citation: U.S. Patent No. 5,985,856, "Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof," Stella et al., granted Nov 16, 1999.
• Brief description: Discloses N-phosphoryloxymethyl (phosphonooxymethyl) derivatives of secondary and tertiary amines as water-soluble prodrugs, and methods of making them; exemplified with loxapine and cinnarizine. This is the chemistry platform the '586 itself identifies as the basis for its phosphoryloxymethyl quaternary piperazinium compounds. Notably, Valentino J. Stella is a named co-inventor of the '586, so this patent is applicant-linked art.
• § 102 assessment: No anticipation of any of claims 1–21. The reference is generic to an amine-prodrug method of making/moiety; it does not disclose the 4-phenyl-pyridine core, let alone the specific claimed quaternary piperazinium compound, and it discloses no emesis-treatment method. Its disclosure of the phosphonooxymethyl moiety is a sub-element, not the full claimed subject matter.
• § 103 role: High — this is the primary "prodrug-forming chemistry" reference. The '586 specification itself frames the invention as an improvement over the '856 patent (arguing the '856 does not show how the moiety affects stability, tolerability, bioavailability, metabolism, or toxicity). A challenger would combine '856 with Bös ('375/'483) to argue the claimed water-soluble netupitant prodrug was obvious. Claims implicated: principally 1, 10 (the phosphonooxymethyl piperazinium compound) and dependents 6–9, 11–13, 16–17, 19–21 (injection/dose/co-therapy).

2. US 6,297,375 — Bös et al. (Hoffmann-La Roche), granted Oct 2, 2001

• Full citation: U.S. Patent No. 6,297,375 B1, "4-phenyl-pyridine derivatives," Bös et al., app. 09/507,456 filed Feb 22, 2000; priority EP 99103504 (Feb 24, 1999) and EP 99123689 (Nov 29, 1999); granted Oct 2, 2001.
• Brief description: Discloses a genus of 4-phenyl-pyridine NK-1 receptor antagonists (65 claims), expressly including netupitant — 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide — and its morpholino analog. It reports NK-1 binding data (pKi ≈ 9.0), gerbil foot-tapping antagonism, ferret/motion-sickness emesis models (ED₅₀ ≈ 0.1 mg/kg p.o.), and states the compounds are useful for "emesis." This is the reference the '586 specification identifies as describing "netupitant… for the prevention of CINV."
• § 102 assessment: No anticipation of claims 1–21 as issued, because Bös discloses the tertiary-amine parent (netupitant), not the quaternary N-phosphonooxymethyl piperazinium (fosnetupitant) or the other structures drawn in the claims; the claimed method thus requires an agent Bös does not disclose.
  • ⚠️ Exception to flag: Bös is a disclosing reference for netupitant and for the antiemetic use of netupitant. Therefore, if any independent claim (most plausibly claim 18) draws the netupitant structure rather than the fosnetupitant structure, US 6,297,375 would be a § 102(a)/(b) anticipation reference for that claim and its dependents, and US 6,479,483 would be a companion § 102 reference. This is the single highest-risk § 102 scenario in the set, and it turns entirely on which structure appears in the claim images. Verify the claim drawings before relying on the "no anticipation" conclusion for claim 18.
• § 103 role: Primary obviousness reference against all claims not drawn to netupitant itself (this is exactly how Gland Pharma pleaded it in the D.N.J. ANDA case — "Bös" plus WO 99/33846, DeGoey, Funk, Krise I, Oslob, the ALOXI® label, and the EMEND® label).

3. US 6,303,790 — Hilpert et al. (Hoffmann-La Roche), granted Oct 16, 2001

• Full citation: U.S. Patent No. 6,303,790 B1, "Process for the preparation of pyridine derivatives," Hilpert et al., granted Oct 16, 2001.
• Brief description: A process/method-of-manufacture patent directed to preparing 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide (DK 1103545 T3 family process).
• § 102 assessment: No anticipation of any claim. A process patent discloses how to make a compound; it discloses neither the specific claimed prodrug structures nor a method of treating emesis. Even if it disclosed the parent compound, anticipation of a method-of-treatment claim requires disclosure of the treating step.
• § 103 role: At most a secondary process/conception reference; of low independent weight.

4. US 6,479,483 — Bös et al. (Hoffmann-La Roche), granted Nov 12, 2002

• Full citation: U.S. Patent No. 6,479,483 B2, "4-phenyl-pyridine derivatives," Bös et al., app. 09/901,982 filed Jul 10, 2001 (divisional of 09/507,456), granted Nov 12, 2002.
• Brief description: Same 4-phenyl-pyridine NK-1 antagonist genus as the '375 (X = —C(O)N(R⁵)— subgenus), claiming inter alia N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide and related nicotinamides; discloses NK-1 antagonist utility.
• § 102 assessment: No anticipation of claims 1–21 as issued, for the same reason as the '375 (discloses tertiary amines/N-benzyl nicotinamides, not the claimed quaternary phosphonooxymethyl piperazinium). It is a companion § 102 reference only in the same contingent scenario described above (if a claim draws a compound actually disclosed by the Bös family).
• § 103 role: High, as a genus/species reference for the 4-phenyl-pyridine scaffold.

5. US 6,531,597 — Hoffmann-Emery et al. (Hoffmann-La Roche), granted Mar 11, 2003

• Full citation: U.S. Patent No. 6,531,597 B2, "Process for preparation of 2-phenyl acetic acid derivatives," Hoffmann-Emery et al., granted Mar 11, 2003.
• Brief description: Synthetic-process patent for 2-phenyl acetic acid intermediates.
• § 102 assessment: No anticipation of any claim — process/intermediate art; no compound or treatment disclosure of the claimed subject matter.
• § 103 role: Minimal; background process art.

6. US 6,593,472 — Hoffmann et al. (Hoffmann-La Roche), granted Jul 15, 2003

• Full citation: U.S. Patent No. 6,593,472 B2, "NK-1 receptor active amine oxide prodrugs," Hoffmann, Poli, Schnider & Sleight, app. 09/904,059 filed Jul 12, 2001; priority EP 00115287 (Jul 14, 2000); granted Jul 15, 2003.
• Brief description: Discloses N-oxide (amine-oxide) prodrugs of 4-phenyl-pyridine NK-1 antagonists, e.g., 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-oxy-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide. Expressly states the purpose is to render the parent (poorly water-soluble) compounds suitable for parenteral/intramuscular (bolus) administration — a direct teaching of the same "make the netupitant class water-soluble for injection" problem the '586 addresses.
• § 102 assessment: No anticipation of any claim. The reference discloses N-oxides, whereas the '586 claims require a phosphonooxymethyl quaternary piperazinium (and/or other specifically drawn structures) — a chemically distinct prodrug class. The '586 specification even states "the invention excludes all N-oxide forms." Different compound type ⇒ no § 102.
• § 103 role: High. Along with '026 and '370, it supplies the motivation ("overcome low water solubility; enable parenteral/IV dosing of a 4-phenyl-pyridine NK-1 antagonist") that a challenger would pair with '856 (phosphonooxymethyl chemistry) and Bös (the drug) to argue the claimed prodrug was obvious. Claims implicated: 1, 6, 10, 13, 16–17 (parenteral/IV dosing and the compound class).

7. US 6,719,996 — Kuentz et al. (Hoffmann-La Roche), granted Apr 13, 2004

• Full citation: U.S. Patent No. 6,719,996 B2, "Galenic composition for low bioavailability medicaments," Kuentz et al., granted Apr 13, 2004.
• Brief description: Galenic/pharmaceutical formulation patent addressing low-bioavailability active agents.
• § 102 assessment: No anticipation — formulation art; does not disclose the claimed compounds or the emesis-treatment method.
• § 103 role: Low-to-moderate; general formulation background for claims reciting route/dose (6–7, 10, 13, 16–17, 19–20).

8. US 6,747,026 — Hoffmann et al. (Hoffmann-La Roche), granted Jun 8, 2004

• Full citation: U.S. Patent No. 6,747,026 B2, "NK-1 receptor active amine oxide prodrugs," Hoffmann, Poli, Schnider & Sleight, granted Jun 8, 2004 (divisional of 09/904,059; pre-grant pub. US 2004/0048901 A1, Mar 11, 2004); priority EP 00115287 (Jul 14, 2000).
• Brief description: The mono-N-oxide derivatives of 4-phenyl-pyridine compounds; this is the reference the '586 specification singles out — "These N-Oxide derivatives are reportedly intended to overcome limitations on the parent compounds… such as solubility or pharmacokinetic limitations. However, no physicochemical or biological data of the mono-N-Oxide derivatives are reported in the '026 patent."
• § 102 assessment: No anticipation of any claim. Discloses N-oxides; the '586 claims exclude N-oxide forms and instead claim a phosphonooxymethyl quaternary salt (and/or other structures). Different compound ⇒ no § 102.
• § 103 role: High as a "motivation" reference for the solubility/parenteral problem; the '586's own characterization of it is part of the prosecution narrative.

9. US 6,806,370 — Hoffmann et al. (Hoffmann-La Roche), granted Oct 19, 2004

• Full citation: U.S. Patent No. 6,806,370 B2, "NK-1 receptor active amine oxide prodrugs," Hoffmann, Poli, Schnider & Sleight, app. 10/645,895 filed Aug 21, 2003 (division of 10/337,543, which is a division of 09/904,059 → US 6,593,472); priority EP 00115287 (Jul 14, 2000); granted Oct 19, 2004; 13 claims.
• Brief description: Third member of the amine-oxide prodrug family (same disclosure family as '472 and '026).
• § 102 assessment: No anticipation of any claim — same reasoning as '472/'026.
• § 103 role: Cumulative to '472/'026.

NPL-1. Kramer et al., Science 281(5383):1640–1645 (1998)

• Brief description: Reports that blockade of central substance P (NK-1) receptors produces antidepressant activity (MK-869/aprepitant clinical data); the '586 cites it for the proposition that NK-1 antagonists have been trialed for anxiety, depression, psychosis, schizophrenia and emesis.
• § 102 assessment: No anticipation of any claim. A pharmacological mechanism/clinical-trial paper that discloses neither the claimed compound nor the claimed dosing/combination regimen.
• § 103 role: Background/state-of-the-art only.

NPL-2. Gesztesi et al., Anesthesiology 93(4):931–937 (2000)

• Brief description: Reports that an NK-1 (substance P) antagonist prevents post-operative vomiting after abdominal hysterectomy — i.e., it documents the antiemetic utility of NK-1 antagonists (PONV).
• § 102 assessment: No anticipation of any claim. Discloses neither the claimed compound nor the claimed regimen; at most it establishes NK-1 antagonism as a known antiemetic mechanism. Claims it touches on obviousness: 2 and 12 (PONV/CINV indications) and the general "treating emesis" limitation of claims 1/10/14/18.
• § 103 role: Background, corroborating known antiemetic utility of the class.

3. Family members and other references relevant to § 102/§ 103 that are not on the face

4. Bottom line

• § 102 (anticipation): No front-page reference anticipates claims 1–21 as issued. Every cited U.S. patent discloses either (a) the tertiary-amine 4-phenyl-pyridine parent (netupitant) and its antiemetic utility (Bös '375/'483), (b) N-oxide prodrugs of that class ('472, '026, '370), (c) a generic phosphoryloxymethyl amine-prodrug chemistry platform ('856), or (d) process/formulation art ('790, '597, '996). None discloses the specific quaternary phosphonooxymethyl piperazinium (and/or other structures) drawn in the claims together with the claimed method of treating emesis, which is what § 102 requires.
• Single material caveat: Because US 6,297,375 discloses netupitant itself and expressly discloses its antiemetic use, any independent claim whose drawing depicts netupitant (most plausibly claim 18, unverified) would be anticipated by US 6,297,375, with US 6,479,483 as a companion reference. This must be checked against the granted claim drawings.
• § 103 (obviousness): The cited art is configured as an obviousness combination: Bös '375/'483 (the drug + its antiemetic use) + '856 (phosphonooxymethyl water-solubilizing prodrug chemistry) + '472/'026/'370 (express motivation to make this class water-soluble for parenteral administration) ± Kramer/Gesztesi (known NK-1 antiemetic utility). That is precisely the obviousness theory Gland Pharma pleaded against the '586 in Helsinn v. Gland Pharma, D.N.J. No. 3:22-cv-04635 (resolved by consent judgment in January 2023), which recited "Bös; WO 99/33846; DeGoey; Funk; Krise I; Oslob; the ALOXI® label; and the EMEND® label."

References I could not verify to a primary source and therefore flag: (i) the exact structures drawn in the '586 claim images (determines the claim-18 § 102 exposure to US 6,297,375); (ii) the file-wrapper PTO-892 for App. 13/864,381 (whether any reference was cited/applied beyond the face listing); (iii) filing dates for US 6,303,790, 6,531,597, 6,719,996, and 6,747,026, which were not surfaced in the sources reached and are reported above only by their grant dates.

I'll ground this analysis in the actual prior-art references. Let me verify the key references.

Let me verify the granted claims and the EMEND/fosaprepitant label teaching.

Obviousness Analysis — U.S. Patent No. 8,895,586 under 35 U.S.C. § 103

Prepared: April 26, 2026
Subject: U.S. 8,895,586 B2, "Methods of Treating Emesis" (app. 13/864,381; filed Apr. 17, 2013; priority to U.S. Provisional 61/564,537, filed Nov. 29, 2011; granted Nov. 25, 2014; 21 claims, no drawings; assignee Helsinn Healthcare SA)

Note on sources: This analysis builds on the two earlier sections (Patent summary; Litigation summary) rather than repeating them. The references analyzed are (i) those the '586 specification itself identifies in its Background/prior-art discussion — U.S. 6,297,375 (Hoffmann-La Roche), U.S. 6,747,026 (Hoffmann-La Roche), U.S. 5,985,856 (University of Kansas), Kramer et al., Gesztesi et al.; and (ii) the references Gland Pharma actually pleaded for the '586 patent in its Paragraph IV counterclaim — Bös; WO 99/33846; DeGoey; Funk; Krise I; Oslob; the ALOXI® label; the EMEND® label. I have added bibliographic detail (e.g., that "Bös" for the related '450 patent is pleaded as U.S. 6,479,483) where I could verify it; where I could not, I say so.

1. Governing law, effective date, and the resulting prior-art universe

The '586 claims priority to Nov. 29, 2011. Because the application was filed after March 16, 2013 but claims benefit of a pre-March 16, 2013 filing date, there is a threshold question of whether pre-AIA §§ 102/103 or the AIA first-inventor-to-file provisions apply. Under the AIA transition rules, the AIA § 102/103 regime governs the '586 only if at least one claim has an effective filing date on or after March 16, 2013. If the granted claims are fully supported by provisional 61/564,537 (Nov. 29, 2011) — and/or by the continuation-in-part 13/478,361 filed May 23, 2012, which issued as U.S. 8,426,450 — then pre-AIA § 103 applies. This matters here because:

• Pre-AIA § 103(c) permits an applicant to disqualify certain commonly-owned § 102(e)/(f)/(g) art; and
• Pre-AIA § 102(e) treats published applications and patents by filing date, whereas AIA § 102(a)(2) treats them by effective filing date with different exceptions.

Analytical consequence: the safest approach is to analyze under both regimes using references that are prior art as of Nov. 29, 2011 under either regime (i.e., patents and printed publications published more than one year before, or otherwise statutory). All of the primary references below predate Nov. 29, 2011 by years, so the outcome is unaffected. I flag this only because it affects which secondary references (e.g., the applicants' own WO 2013/082102, published June 6, 2013) are usable — and that reference is not prior art to the '586's Nov. 2011 priority date.

Legal framework applied: Graham v. John Deere Co., 383 U.S. 1 (1966) (scope and content of prior art; differences; PHOSITA level; secondary considerations); KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007) (predictable variations; "finite number of identified, predictable solutions"; motivation may come from design incentives, market demand, or the nature of the problem); In re O'Farrell (reasonable expectation of success, not absolute certainty); Altana Pharma v. Teva / Takeda v. Alphapharm (lead-compound framework); MPEP § 2143 (articulated reasons A–G).

2. Person having ordinary skill in the art (PHOSITA)

A medicinal chemist or pharmaceutical scientist with at least a Ph.D. (or M.S. plus several years' experience) in organic/medicinal chemistry or pharmaceutics and 2–5 years of experience in the development of NK1-receptor-antagonist antiemetics, including practical familiarity with:

• the 4-phenyl-pyridine NK1 antagonist chemotype (aprepitant, netupitant) and the NK1/5-HT3/corticosteroid CINV treatment paradigm;
• prodrug design, specifically bioreversible derivatization of tertiary aliphatic amines (N-oxides, quaternary ammonium salts, N-phosphoryloxymethyl/N-phosphonooxymethyl quaternary ammonium phosphates);
• parenteral formulation and the problem of injectable-site irritation with poorly soluble, amphiphilic NK1 antagonists; and
• the FDA-approved prescribing information for EMEND® (aprepitant/fosaprepitant) and ALOXI® (palonosetron).

This is not a narrowly defined artisan. It is exactly the artisan who would have been working on IV line extensions of netupitant in the 2009–2011 window.

3. The claimed subject matter, as construed

From the granted claim listing (DrugPatentWatch claim text) and the "21 Claims, No Drawings" face data:

Construction point 1 — the compound of claim 1. The specification's compound GA1 is 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium — i.e., fosnetupitant, the IV AKYNZEO ingredient. The '586's own Background identifies netupitant as a known, clinically developed NK1 antagonist. I therefore analyze claim 1 as reciting the N-phosphonooxymethyl quaternary ammonium prodrug of netupitant. Caveat carried forward from the earlier summary: the claim structures 10, 14, and 18 are drawn (image) and I could not visually verify which of GA1–GA8 each recites; the analysis below flags where this matters.

Construction point 2 — "treating emesis." Method-of-treatment claims with no required mechanism, no dose in claim 1, no route in claim 1, and no co-therapy in claim 1. Claim 1 is therefore the broadest claim and the one most vulnerable.

Construction point 3 — the specification's admissions. The Background of the '586 is an admissions-rich document that materially shortens the obviousness inquiry under In re Fout / MPEP 2129:

• Netupitant is known and is "currently under clinical development in combination with palonosetron … for the prevention of chemotherapy-induced-nausea and vomiting (CINV)" — an admission of the compound class, the indication, and the combination.
• U.S. 6,747,026 describes "Mono-N-Oxide derivatives of 4-phenyl-pyridine compounds … reportedly intended to overcome limitations on the parent compounds that would otherwise limit their clinical usefulness, such as solubility or pharmacokinetic limitations."
• U.S. 5,985,856 describes "water soluble N-phosphoryloxymethyl derivatives of secondary and tertiary amines" and "the use of such derivatives to improve the solubility profiles."

In other words, the specification concedes that (a) the parent drug, (b) the indication, (c) the combination, and (d) the two prodrug strategies (N-oxide and N-phosphoryloxymethyl) were all known. The only thing arguably new is the selection of one prodrug strategy over the other, applied to one specific compound.

4. The prior-art references and what each teaches

5. Combination-by-combination obviousness analysis

5(a) Claims 1–5 — the core method

Combination I: Bös ('375/'483) + Roche '026 + '856/WO '846 + Krise I.

Element-by-element:

1. Administering a compound — Bös discloses netupitant, a selective NK1 antagonist; '026's formula II covers the netupitant class and expressly identifies the 4-o-tolyl-pyridine/3,5-bis-CF₃-isobutyramide scaffold; the piperazine ring at the 2-position maps onto '026's "5 or 6 member nitrogen containing heterocyclic ring … pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, morpholin-4-yl…" definitions.
2. The N-phosphonooxymethyl quaternary ammonium on that piperazine nitrogen — '856/WO '846 claim 1 and Krise I disclose precisely the promoiety –CH₂–O–P(O)(OH)₂ appended to a tertiary amine nitrogen that "may be joined to form a ring." Netupitant's N4-methylpiperazine provides exactly the tertiary, ring-forming amine the reference contemplates.
3. "or a pharmaceutically acceptable salt thereof" — '856/WO '846 expressly contemplate pharmaceutically acceptable cations X and anions A, and pH-adjusted, lyophilizable, injectable compositions. Salt selection is, in any event, a routine optimization (Pfizer v. Apotex; In re Aller).
4. "treating emesis" — Bös already discloses emesis; '026 and the EMEND label independently tie NK1 antagonists and their prodrugs to emesis and CINV.
5. "in a patient in need thereof … therapeutically effective amount" — conventional claim language; the dose is a result-effective variable left to the artisan (see §5(b)).

Why the combination is motivated (KSR / MPEP 2143 factors):

• (A) Same field / analogous art. All four references are in NK1-antagonist chemistry and antiemetic drug development; '375 and '026 share the same assignee (Roche) and the same 4-phenyl-pyridine chemotype. KSR holds that "if a technique has been used to improve one device [here, molecule], and a person of ordinary skill in the art would recognize that it would improve similar devices in the same way, using the technique is obvious."
• (B) Same problem, and the prior art states the problem and the solution. '026 states in terms: the parent compounds "have limited water solubility, not allowing bolus injections," and the fix is a bioreversible derivative "suitable for parenteral and intramuscular application." The '586's own stated object is the identical one: "derivatives of 4-phenyl-pyridine compounds … with enhanced physicochemical and/or biological properties." Where the prior art articulates the very deficiency the inventors set out to cure, motivation is not speculative — it is on the face of the reference.
• (C) The references themselves point to the claimed promoiety. '026 steers to amine-oxide derivatization; '856/Krise I teaches that the N-phosphoryloxymethyl variant yields a quaternary ammonium salt that is dramatically more water-soluble, stable at physiological pH without cosolvent, and bioreversibly cleaved via phosphatase + spontaneous N-hydroxymethyl decomposition to liberate the parent amine. A PHOSITA seeking an injectable netupitant has a finite number of identified, predictable solutions (N-oxide, N-phosphoryloxymethyl, acyloxymethyl, water-soluble salts) — precisely the KSR "finite number of identified, predictable solutions" fact pattern.
• (D) Predictable results / reasonable expectation of success. Krise I's beagle-dog study confirmed in vivo IV conversion of an N-phosphonooxymethyl prodrug to parent drug. DeGoey (2009) and Oslob (2009) extend the platform to two more drug classes. By the Nov. 2011 priority date, the technique was not "obvious to try" in the Kubin sense — it was routine and demonstrated, with a reasonable expectation of success.
• (E) Commercial/market pressure. Both parties knew netupitant was being developed for CINV; an IV formulation of a highly emetogenic-chemotherapy antiemetic is an obvious product-line extension, and the '586 specification itself frames the work as responding to clinical need.
• (F) The '586's own specification supplies the admission. By conceding that netupitant, the indication, the palonosetron combination, the N-oxide prodrug approach, and the N-phosphoryloxymethyl prodrug approach were all known, the specification effectively concedes that the claim-1 compound is the product of combining known elements. The only asserted advance is that the '026 and '856 references lacked data on stability/tolerability/bioavailability. Lack of data in a reference is not a teaching away; and under KSR, a predicted, predictable benefit suffices even where the reference provides no working examples.

Claim 2–5 limitations: CINV, RINV, PONV, moderately/highly emetogenic chemotherapy, and acute-plus-delayed emesis are all recited in the EMEND and ALOXI labels and in the Kramer and Gesztesi literature the applicants themselves cite. Merely naming an indication that the prior art already associates with the drug's mechanism adds nothing patentable (In re Kulling; Perricone v. Medicis). Note in particular that the ALOXI and EMEND labels both expressly cover delayed CINV and both emetogenic categories, and that combination NK1+5-HT3 regimens for highly emetogenic chemotherapy were in the labels.

5(b) Claims 6–7 and 10–13 — injection and 10–200 mg

• Injection (claims 6, 10, 11): this is the entire purpose of the prodrug strategy taught in '026 and '856 — parenteral administration of a parent drug that "do[es] not allow bolus injections." The specification's own description says the '856 promoiety was used "to improve the solubility profiles," and the specification elsewhere states a single IV dose is "intravenously administered at a dosage of from about 10 mg to about 200 mg … based on the weight of the netupitant component of the molecule." That dose language, repeated in the '586's own specification and in WO 2013/082102, is an admission that the route and range are conventional.
• Dose range, 10–200 mg (claims 7, 12, 17, 20): obtaining a therapeutically effective dose by routine optimization is not inventive where the parameter is result-effective and the prior art provides guidance (In re Aller; In re Boesch). Guidance here is abundant: the EMEND label's fosaprepitant/aprepitant IV dosing and the specification's own recitation of 10–200 mg / 50–150 mg / 75–125 mg / ~100 mg (and the eventual clinical 235 mg fosnetupitant equivalence to 300 mg oral netupitant) show the range was reached by ordinary dose-finding. Note the odd range "from about 75 mg to about 12.5 mg" appears as a typographical artifact in the Google-rendered text of the '586; it should not be read as a deliberate recitation.

5(c) Claims 8–9 and 14–17 — palonosetron ± dexamethasone

Combination II: Combination I + EMEND® label + ALOXI® label (+ Bös, which already pairs netupitant with palonosetron in the applicants' own admission).

• The '586's Background states that netupitant is "currently under clinical development in combination with palonosetron … for the prevention of CINV." That is an on-the-face admission that the two-drug combination was known.
• The EMEND label discloses the three-drug paradigm — NK1 antagonist (as the IV N-phosphoryl prodrug fosaprepitant) + 5-HT3 antagonist + dexamethasone — for acute and delayed CINV from highly and moderately emetogenic chemotherapy, including a dexamethasone taper (12 mg PO day 1, 8 mg days 2–4), which is the regimen recited in the '586 specification and in dependents of claim 14.
• The ALOXI label supplies palonosetron specifically: 0.25 mg IV (free base) and 0.5 mg oral, with the same CINV indications.
• The motivation is not merely "combine two antiemetics": it is that the mechanisms are complementary and non-redundant (NK1 receptor blockade vs. 5-HT3 receptor blockade) and the art already used them together while titrating dexamethasone for CYP3A4 interaction reasons. Combination of known active agents with a shared indication is obvious where there is a reasoned rationale or a reasonable expectation of additive benefit (KSR; In re Merck & Co.; Eli Lilly v. Zenith Goldline).

5(d) Claim 18 and dependents 19–21

Claim 18 recites a different drawn compound. Two scenarios:

• If claim 18 recites netupitant itself (or a salt/phosphate thereof), it is anticipated or at minimum rendered obvious by Bös/'375 alone, with the method step supplied by the same references' express emesis indication.
• If claim 18 recites one of the N-oxide species GA4–GA8 (e.g., GA8 = netupitant piperazine 1-oxide), then U.S. 6,747,026 is squarely anticipatory or at least prima facie obvious art: '026's generic formula covers a 4-o-tolyl-pyridine, 3,5-bis-CF₃-phenyl isobutyramide bearing a piperazin-1-yl N-oxide, and '026 expressly names the morpholine-N-oxide analog 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[6-(4-oxy-morpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-isobutyramide. The claim-18 method step ("treating emesis") is also in '026's express utility statement ("emesis by the administration of NK-1 receptor antagonists").
• Internal-consistency flag: the '586 specification also states "the invention excludes all N-oxide forms," while simultaneously listing N-oxide species GA4–GA8. This tension is a claim-construction and written-description issue independent of § 103, but it is worth noting: if a granted claim recites an N-oxide species, the claim and the specification's own disclaimer may be in direct conflict, which itself invites a § 112 challenge (as Gland pleaded: "invalid as indefinite and not enabled").

6. The strongest single-reference-plus-secondary-reference case (for a petition or an invalidity contention)

Primary: U.S. 6,747,026 (Roche).
Secondary: U.S. 5,985,856 / WO 99/33846 (Kansas/Stella) and Krise I (1999).
Tertiary: Bös (netupitant) and the EMEND label (IV NK1 prodrug + 5-HT3 + steroid for CINV).

The narrative a challenger would present: by 2004 Roche had already taught that the netupitant chemotype's poor aqueous solubility prevented bolus injection and that the fix was bioreversible derivatization of the ring tertiary amine; by 1999 Stella had taught the specific N-phosphoryloxymethyl quaternary ammonium promoiety, its synthesis via di-tert-butyl chloromethyl phosphate, and its phosphorylation-then-spontaneous-hydrolysis release mechanism with in vivo proof; by 2009 DeGoey and Oslob had shown the platform was generic across drug classes; and the EMEND label had commercialized precisely this concept on a competing NK1 antagonist and a three-drug CINV regimen. All that remained was to run the known reaction on the known compound, which the '586's own Examples do — the specification's Example 1 uses di-tert-butyl phosphite → potassium di-tert-butyl phosphate → chloromethylation with chloroiodomethane → quaternization → deprotection, i.e., the Krise I/'856 route substantially verbatim.

That is a textbook KSR case: known compound + known promoiety + known reaction + known use, with a stated problem solved in a stated way and predictable results.

7. Counterarguments and secondary considerations — and how they fare

8. Explicit uncertainties and where the case could be stronger or weaker

1. The drawn claim structures (10, 14, 18) remain unverified. The earlier summary flagged this and I could not resolve it by search. Claim 1's text and dependents 2–9 are confirmed; the identity of the third compound in claim 18 is not. If claim 18 recites GA8 or another N-oxide, the '026 reference becomes near-anticipatory and the case is materially stronger. If claim 18 recites another phosphonooxymethyl species, the same '856/Krise I rationale applies. Verification against the granted patent image is essential before relying on any claim-18-specific conclusion.
2. "Bös" is not conclusively identified for the '586 specifically. Gland's counterclaims identify U.S. 6,479,483 (Bös) as "Bös" in the '450 counterclaim; the '586 counterclaim paragraph I retrieved is truncated after "Bös; WO '846;…". It is highly likely the same reference was intended, but I have not verified the complete '586-specific list. The composition of that list (whether it includes, e.g., DeGoey, Funk, Krise I, Oslob, ALOXI and EMEND) is drawn from the earlier Litigation summary rather than from a document I re-retrieved in this pass.
3. I could not obtain the EMEND/Aprepitant PI text in this session (the searches were truncated). My statements about the EMEND label — that fosaprepitant is an N-phosphoryl prodrug of aprepitant, IV, used with a 5-HT3 antagonist and dexamethasone for acute and delayed CINV from highly/moderately emetogenic chemotherapy — rest on general knowledge and on corroborating literature retrieved in this session (Tyler et al., Clin. Pharmacol. Drug Dev. 11(12), 1405–1418, which states that "Fosaprepitant (dimeglumine) is a water-soluble N-phosphoryl prodrug of aprepitant that is rapidly converted in vivo to aprepitant" and that the standard of care in the highly-emetogenic setting is "a combination of NK1RAs, 5-HT3RAs, and the glucocorticosteroid dexamethasone"). The label date relative to the Nov. 29, 2011 priority date should be confirmed — on the face of it the fosaprepitant IV approval (2008) predates the priority date, so the label qualifies as prior art, but this should be verified from the PI revision history.
4. Legal-status nuance for § 102(e)/(a)(2) art. If any reference is relied on as a pre-AIA § 102(e) or AIA § 102(a)(2) reference (patent/published application), the effective-date analysis in § 1 matters, as does the common-ownership exception. None of the primary references above needs that treatment — all are § 102(b)/(a)(1)-type printed publications or patents more than a year before the critical date.
5. No PTAB record exists. As the earlier Litigation summary establishes, no IPR/PGR/CBM against the '586 has been filed, and the Azurity IPR2025-00945 family targets other Helsinn patents (10,828,297; 8,623,826; 9,186,357; 9,943,515). The Gland case settled by consent judgment in January 2023 without any merits ruling on the '586. So the analysis above is prospective: there is no adjudicated § 103 holding to cite. Any statement that the '586 has been held obvious would be false.
6. This is a technical/analytical assessment, not legal advice, and not a validity opinion. A formal § 103 opinion would require the granted claim images, the complete prosecution histories of the '586 and its parents, the full Paragraph IV detailed statements, and representative-species and secondary-considerations evidence.

9. Bottom line

Under Graham/KSR, the claims of U.S. 8,895,586 are, on the available record, strongly vulnerable to a § 103 challenge, most plausibly mounted as:

• Claims 1–5: Bös ('375/'483, netupitant + emesis) in view of U.S. 6,747,026 (netupitant chemotype has solubility limiting bolus injection; make an amine-derived, bioreversible, parenterally suitable prodrug) in view of U.S. 5,985,856 / WO 99/33846 and Krise I (the specific N-phosphoryloxymethyl quaternary ammonium promoiety, its synthesis and its phosphatase-mediated bioreversion), optionally with the EMEND and ALOXI labels for the CINV/emetogenic-category/delayed-emesis limitations.
• Claims 6–7, 10–13: the same combination, since injectability is the stated purpose of the prodrug art, plus routine optimization for the 10–200 mg range.
• Claims 8–9, 14–17: add the EMEND label (NK1 prodrug + 5-HT3 antagonist + dexamethasone for acute and delayed CINV) and the ALOXI label (palonosetron 0.25 mg IV); the applicants' own Background already concedes the netupitant + palonosetron combination.
• Claims 18–21: depends on the drawn structure; if it is an N-oxide or netupitant itself, U.S. 6,747,026 (or Bös) is close to anticipatory.

The principal remaining foothold for the patentee is unexpected results, and the patent's own stability and PK data are the place to look for it — but because the claims recite a generic "pharmaceutically acceptable salt," any such showing must be commensurate with the full claim scope, which the current data (salt-specific stability, single-compound PK) likely cannot support.